Life After s Loss: Impact of Hepatitis B s Antigen Loss on Future Patient Outcomes.
作者信息
Huang Daniel Q, Lim Seng Gee
机构信息
Division of Gastroenterology and Hepatology Department of Medicine National University Hospital Singapore.
Department of Medicine Yong Loo Lin School of Medicine National University of Singapore Singapore.
出版信息
Clin Liver Dis (Hoboken). 2021 Jan 13;16(6):262-265. doi: 10.1002/cld.983. eCollection 2020 Dec.
Abstract
摘要
相似文献
1
Life After s Loss: Impact of Hepatitis B s Antigen Loss on Future Patient Outcomes.乙肝表面抗原消失后的生活：乙肝表面抗原消失对未来患者预后的影响。
Clin Liver Dis (Hoboken). 2021 Jan 13;16(6):262-265. doi: 10.1002/cld.983. eCollection 2020 Dec.
2
Clinical implication of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level on hepatitis B e-antigen loss or seroconversion in hepatitis B e-antigen positive patients.血清紫藤凝集素阳性Mac-2结合蛋白水平对乙肝e抗原阳性患者乙肝e抗原消失或血清学转换的临床意义
Hepatol Res. 2016 Oct;46(11):1065-1073. doi: 10.1111/hepr.12655. Epub 2016 May 26.
3
Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.在接受长期恩替卡韦治疗的HBeAg阳性慢性乙型肝炎患者中，聚乙二醇化干扰素序贯联合治疗可导致乙肝表面抗原消失和HBeAg血清学转换。
Antimicrob Agents Chemother. 2015 Jul;59(7):4121-8. doi: 10.1128/AAC.00249-15. Epub 2015 May 4.
4
Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability.核苷类似物治疗期间的乙肝表面抗原血清学清除：表面抗原动力学、结局及持久性
J Gastroenterol. 2016 May;51(5):487-95. doi: 10.1007/s00535-015-1128-2. Epub 2015 Oct 7.
5
Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B.糖皮质激素与α干扰素序贯联合治疗与单用α干扰素治疗HBeAg阳性慢性乙型肝炎的比较
Cochrane Database Syst Rev. 2002(2):CD000345. doi: 10.1002/14651858.CD000345.
6
Occupational exposure to human immunodeficiency virus and hepatitis B virus: a comparative analysis of risk.职业性接触人类免疫缺陷病毒和乙型肝炎病毒：风险的比较分析
Am J Med. 1992 May;92(5):503-12. doi: 10.1016/0002-9343(92)90747-y.
7
Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy.乙肝e抗原阴性肝硬化患者停止或继续核苷类似物治疗后的乙肝表面抗原消失情况及临床结局
J Viral Hepat. 2017 Jul;24(7):599-607. doi: 10.1111/jvh.12683. Epub 2017 Feb 22.
8
Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients.抗逆转录病毒治疗的 HIV-乙型肝炎病毒感染患者中乙型肝炎表面抗原和 envelope 抗原的动力学和替诺福韦治疗反应的预测。
AIDS. 2012 May 15;26(8):939-49. doi: 10.1097/QAD.0b013e328352224d.
9
Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.血清乙型肝炎表面抗原水平可预测乙型肝炎 e 抗原血清学转换者的表面抗原丢失。
Gastroenterology. 2011 Aug;141(2):517-25, 525.e1-2. doi: 10.1053/j.gastro.2011.04.046. Epub 2011 Apr 28.
10
Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B.乙型肝炎 e 抗原阴性慢性乙型肝炎患者接受核苷（酸）类似物治疗期间乙型肝炎表面抗原动力学。
Liver Int. 2017 Nov;37(11):1642-1650. doi: 10.1111/liv.13432. Epub 2017 Apr 26.
引用本文的文献
1
Steatosis and Interferon Associated with HBsAg Immune Control in Chronic Hepatitis B: A Real-World Propensity Score-Matched Study.脂肪变性和干扰素与慢性乙型肝炎患者HBsAg免疫控制的相关性：一项倾向评分匹配的真实世界研究
Biomedicines. 2025 Jun 24;13(7):1538. doi: 10.3390/biomedicines13071538.
2
3
HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure.HBsAg 消失作为慢性 HBV 感染的治疗终点：HBV 治愈。
Viruses. 2022 Mar 22;14(4):657. doi: 10.3390/v14040657.
本文引用的文献
1
Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B.慢性乙型肝炎患者接受核苷酸类似物和聚乙二醇干扰素治疗后乙肝表面抗原消失的持久性
Hepatol Commun. 2019 Oct 10;4(1):8-20. doi: 10.1002/hep4.1436. eCollection 2020 Jan.
2
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference.慢性乙型肝炎临床试验设计和终点的指导原则——2019 年 EASL-AASLD HBV 治疗终点会议报告。
J Hepatol. 2020 Mar;72(3):539-557. doi: 10.1016/j.jhep.2019.11.003. Epub 2019 Nov 12.
3
Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).核苷（酸）类似物停药后慢性乙型肝炎患者持续应答有限：一项随机对照试验（多伦多停药研究）的结果。
Gut. 2019 Dec;68(12):2206-2213. doi: 10.1136/gutjnl-2019-318981. Epub 2019 Aug 28.
4
Durability of Spontaneous and Treatment-Related Loss of Hepatitis B s Antigen.乙肝表面抗原自发及治疗相关消失的持久性。
Clin Gastroenterol Hepatol. 2020 Mar;18(3):700-709.e3. doi: 10.1016/j.cgh.2019.07.018. Epub 2019 Jul 16.
5
Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses.慢性乙型肝炎病毒感染者中表面抗原自发丢失：系统评价和汇总荟萃分析。
Lancet Gastroenterol Hepatol. 2019 Mar;4(3):227-238. doi: 10.1016/S2468-1253(18)30308-X. Epub 2019 Jan 22.
6
The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation Among Asian Patients With Chronic Hepatitis B: A Systematic Review.乙型肝炎表面抗原在亚洲慢性乙型肝炎核苷（酸）类似物停药中的作用：系统评价。
Hepatology. 2019 Sep;70(3):1045-1055. doi: 10.1002/hep.30474.
7
Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis.与慢性乙型肝炎病毒感染者 HBsAg 血清学清除率相关的因素：系统评价和荟萃分析。
Gastroenterology. 2019 Feb;156(3):635-646.e9. doi: 10.1053/j.gastro.2018.10.027. Epub 2018 Oct 17.
8
Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.乙肝表面抗原血清学清除后肝细胞癌危险因素的系统评价
J Viral Hepat. 2018 Sep;25(9):1026-1037. doi: 10.1111/jvh.12905. Epub 2018 May 2.
9
Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy.乙肝e抗原阴性肝硬化患者停止或继续核苷类似物治疗后的乙肝表面抗原消失情况及临床结局
J Viral Hepat. 2017 Jul;24(7):599-607. doi: 10.1111/jvh.12683. Epub 2017 Feb 22.
10
Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance.系统评价与荟萃分析：乙型肝炎表面抗原血清学清除的慢性乙型肝炎患者中肝细胞癌的发生。
Aliment Pharmacol Ther. 2016 Jun;43(12):1253-61. doi: 10.1111/apt.13634. Epub 2016 Apr 27.
Zotero 插件